Log In
Print
BCIQ
Print
Print this Print this
 

Altropane (NAV5001)

  Manage Alerts
Collapse Summary General Information
Company Alseres Pharmaceuticals Inc.
DescriptionRadioimaging agent that binds to dopamine transporter sites in the brain
Molecular Target Dopamine transporter
Mechanism of ActionDiagnostic; Imaging agent
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationNeurology, Diagnostic
Indication DetailsAid in the differential diagnosis of Parkinsonian syndromes from non-Parkinsonian tremor; Diagnose dementia with Lewy bodies (DLB); Diagnose early-stage Parkinson's disease (PD); Diagnose Parkinson's disease (PD) using single photon emission computed tomography (SPECT) or positron emission tomography (PET); Differentiate Parkinsonian syndrome tremors from non-Parkinsonian tremors; Imaging agent to assess loss of dopamine receptors in Parkinson's disease (PD)
Regulatory Designation

U.S. - Special Protocol Assessment (Aid in the differential diagnosis of Parkinsonian syndromes from non-Parkinsonian tremor)

Partner

Navidea Biopharmaceuticals Inc.; Nordion Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today